BioNetwork 2018

October 10 - 12, 2018

The Ritz-Carlton, Laguna Niguel, CA

1.888.482.6012

Day One Wednesday, October 10, 2018: The BioPharma Partnering Landscape

7:30 am - 8:30 am Breakfast & Registration

img

Zainab Hayat

Program Director
BioNetwork 2018, a WBR event

8:40 am - 8:55 am Chairperson’s Opening Address

Jonathan Gertler - Managing Partner & CEO Back Bay Life Science Advisors
img

Jonathan Gertler

Managing Partner & CEO
Back Bay Life Science Advisors

8:55 am - 9:25 am Keynote: Update from Your Friendly Neighborhood Payer: Balancing Benefits & Cost in the Current Environment

Kent Rogers - SVP, Industry Relations OptumRx
As the leader and owner of the formulary management and procurement function for United Health Group’s PBM, OptumRx, Kent Rogers knows first-hand that the industry lacks a fundamental understanding of the payer landscape -- who payers are, what they do, and most importantly, what drugmakers need to know. Now that the Trump administration is proposing broad sweeping changes to the construct of how the supply chain operates, it is more important than ever that an understanding of where we are informs us of where we may be headed. Kent’s talk will address:
•How do we change the focus from pricing and rebates to value? Is it scalable and could it affect pharma’s pricing decisions?
•Will the proposal to remove barriers of “best-price” when it comes to implementing value-based agreements with pharma encourage pharma to contract more readily in that space? 
•Would the proposal to remove 100% of AMP deter price increases?
•With the proposed changes to the Competitive Acquisition Program in Medicare Part B, if the incentives to profit on the purchase and administration of oncology medications are neutralized – what will be the impact?
•What impact would advertising list prices have in the marketplace with providers or patients?

img

Kent Rogers

SVP, Industry Relations
OptumRx

1.Oncology
Todd Haim, Program Director, SBIR, National Cancer Institute
2.Immunology
Michael Johnson, VP, Business Development, Eli Lily
3.Immuno-oncology
Kaan Certel, Head of Oncology External Innovation, Sanofi
4.Infectious Diseases
5.Neuroscience
Robert Bagdorf, VP, Worldwide Business Development, Pfizer
6.Rare & Orphan Diseases
Joe Whalen, SVP, BD, & Alliance Management, Horizon Pharma
7.Pain
8.Endocrinology

img

Todd Haim

Program Director, Small Business Innovation Research (SBIR) Development Center
National Cancer Institute (NCI)

img

Michael Johnson

VP, Business Development
Eli Lilly

Kaan Certel

Head of Oncology External Innovation
Sanofi

img

Robert Bagdorf

Vice President of Worldwide Business Development
Pfizer Inc.

img

Joe Whalen

SVP, Business Development & Alliance Management
Horizon Pharma

9:55 am - 10:25 am Morning Refreshment Break & Partnering Opens

•What are the implications of recent proposals by the current administration?
•What is the activity we’ve seen since the tax reform earlier this year?
•What can we expect in terms of pharma deal-making over the next year?
•What have been some impacts of the changes in the FDA in the past couple of years?

img

Kristen Slaoui

VP, Head of Business Development, North America
GSK

img

Chris Leo

CMO
Back Bay Life Science Advisors

10:55 am - 11:10 am Biotech Spotlight | Translational Medicine

Ed Zhang - VP, Corporate Development Boston Pharmaceuticals
Boston Pharmaceuticals acquires or partners with innovative molecules from pharmaceutical and biotechnology companies, and transforms them into differentiated therapeutics that improve patients’ lives.
img

Ed Zhang

VP, Corporate Development
Boston Pharmaceuticals

11:10 am - 11:25 am Biotech Spotlight | Oncology

Roland Buelow - CEO Teneobio
Tenebio specializes in cancer therapy through T-cell engagement without Cytokine Release Syndrome.
img

Roland Buelow

CEO
Teneobio

•What are the obstacles in combination IO deal-making?
•What are some innovative deal structures that have happened in the space?
•Beyond PD1, what are the interesting opportunities companies are pursuing?
•Is there opportunity to advance pricing and what are the legal and commercial aspects?

Kaan Certel

Head of Oncology External Innovation
Sanofi

img

Angele Maki

Executive Director, Business Development
Merck

img

Niels Emmerich

VP, Global Head Search & Evaluation
Abbvie

img

Chris DeRespino

Executive Director, Business Development
Amgen

img

Michelle Hoffmann

Senior Vice President
Back Bay Life Science Advisors

11:55 am - 12:10 pm Biotech Spotlight | Oncology

Volker Schellenberger - President & CEO Amunix
Amunix developed a novel format of bispecific T cell engagers (ProTIA) that combine three tumor-targeting modalities: 1) tumor antigen binding; 2) localized activation by tumor-associated proteases; and 3) limited exposure of healthy tissues due to polymer-based prodrug format (EPR effect).
img

Volker Schellenberger

President & CEO
Amunix

12:10 pm - 12:25 pm Biotech Spotlight

9:55 am - 12:10 pm 1:1 Partnering

12:25 pm - 1:25 pm Lunch

•What are the key challenges in conducting diligence? 
•How are some of these challenges best overcome?
•What approaches are most effective in getting validated insights faster?

img

Robert Bagdorf

Vice President of Worldwide Business Development
Pfizer Inc.

img

Debbie Liebert

Managing Director
Domain Associates

img

Jeffrey Warmke

SVP, External Scientific Affairs & Alliance Management
Daiichi Sankyo

img

Jonathan Gertler

Managing Partner & CEO
Back Bay Life Science Advisors

1:55 pm - 2:10 pm Biotech Spotlight | Cardiology

Anil Gulati MD, PhD, FCP - Chairman, Board of Directors Pharmazz, Inc.
img

Anil Gulati MD, PhD, FCP

Chairman, Board of Directors
Pharmazz, Inc.

Hookipa Pharma Inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer; with this goal in mind, we created unique and cutting-edge technologies to reprogram and stimulate the immune system.
img

Torsten Mummenbrauer

Senior Vice President Business Development & Licensing
Hookipa Pharma Inc.

2:25 pm - 2:55 pm Panel: What’s Next in Immunology Deal-making?

Michael Johnson - VP, Business Development Eli Lilly
•What’s hot in the immunology space today?
•How is the science of the field of immunology now affecting the target and therapeutic choices across oncology, neuroscience, and auto-immune diseases?
•What further developments can we see in the space in the coming year?
•What are some of the exciting partnering opportunities to expect?

img

Michael Johnson

VP, Business Development
Eli Lilly

2:55 pm - 3:10 pm Biotech Spotlight | Immunology

David Passmore - Head of Commercial Operations RubrYc Therapeutics
RubrYc Therapeutics integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.
img

David Passmore

Head of Commercial Operations
RubrYc Therapeutics

3:10 pm - 3:25 pm Biotech Spotlight | Immuno-oncology

Alexis Peyroles - CEO OSE Immunotherapeutics
OSE Immunotherapeutics develops innovative immunotherapies in immuno-oncology and autoimmune diseases including neoepitopes innovation Tedopi®, in Phase 3 in NSCLC after checkpoint inhibitor failure and planned to enter Phase 2 in pancreatic cancer (2018), and myeloid checkpoint inhibitor OSE-172 (anti-SIRPa monoclonal antibody) for the treatment of advanced solid tumors.
img

Alexis Peyroles

CEO
OSE Immunotherapeutics

3:25 pm - 3:55 pm Afternoon Refreshment Break

3:55 pm - 4:10 pm Biotech Spotlight | Immunology

Gary Olson - President & CEO Provid
img

Gary Olson

President & CEO
Provid

4:10 pm - 4:25 pm Biotech Spotlight

•Why is there increased industry interest in early stage collaborations?
•How do you overcome some common obstacles in creative early stage collaborations?
•What are the newer trends in early stage collaborations?
•How is biopharma collaboration evolving and what can we expect?

img

Bob Chib

Head, Corporate Strategy & Innovation, Licensing & Alliances
Astellas

img

Nouhad Husseini

VP, Head of Business Development
Regeneron

img

Christoph Pittius

SVP, Research Business Development
City of Hope

img

Joe Whalen

SVP, Business Development & Alliance Management
Horizon Pharma

img

Scott Shaunessy

CEO
ideaPoint

1:25 pm - 5:00 pm 1:1 Partnering

5:00 pm - 6:00 pm Sunset Serenade Reception

6:00 pm - 6:00 pm End of Day One